by Truveta Research | Apr 18, 2025 | Research, Research Insights
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in March 2025 increased relative to December 2024 (+12.96%). Anti-diabetic medication (ADM) prescribing increased from December 2024 to January 2025, then remained relatively stable until March...
by Truveta staff | Mar 7, 2025 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2024 were similar to September 2024 (+1.89%). Anti-diabetic medication (ADM) prescribing rates in December 2024 were similar to those in September 2024 (-0.88%). Among ADMs,...
by Truveta staff | Jan 31, 2025 | Research
Discontinuation within one year was significantly higher in patients without T2D (64.8%) compared to those with T2D (46.5%). When patients experienced greater weight loss, they were less likely to discontinue the GLP-1 RA medications. Among patients with T2D, higher...
by Truveta Research | Dec 16, 2024 | Research, Research Insights
In partnership with Reuters, Truveta Research explored the percentage of patients who received a first-time diagnosis of type 2 diabetes, cardiovascular disease, or sleep apnea within 15 days of their first-time GLP-1 prescriptions. Truveta Research found that for...
by Truveta staff | Dec 6, 2024 | Data
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Research’s GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and...
